ROME GS System Study

Part of paid clinical trials in Escondido, California.

Sponsor
Senseonics, Inc.
Study ID
NCT07518004
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Continuous Glucose Monitoring System — DEVICE
    Eversense 365 Continuous Glucose Monitoring System and ROME GS System

Study Details

The purpose of this clinical investigation is to demonstrate that the proposed physical changes to the ROME GS Sensor do not have any adverse impact on safety and performance when compared to the Eversense 365 Sensor.

Key Dates

Start date
Feb 12, 2026
Status verified
Feb 2026
Primary completion
Aug 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Continuous Glucose Monitoring Device
    Eversense 365 Continuous Glucose Monitoring System and ROME GS System

Primary Outcome Measure

Mean absolute relative difference (MARD) for paired sensor and reference measurements post-insertion. [ Time Frame: 365 days post-insertion ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Headlands Research - AMCR InstituteEscondidoCalifornia92025
Jenine Yager Stone, PhD, MSN, FNP-C
760-466-1520
Flourish Research - Diablo Clinical ResearchWalnut CreekCalifornia94598
Catherine Morimoto
925-930-7267
Mark Christiansen, MD (PRINCIPAL_INVESTIGATOR)
Flourish Research - San AntonioSan AntonioTexas78229
Shelbie Martin
210-949-0122
Sierra Wilson
210-949-0122
Douglas Denham, DO (PRINCIPAL_INVESTIGATOR)
Rainier Clinical Research CenterRentonWashington98057
Tina Mitchell
425-251-1720
Frances Broyles, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Escondido, CA

By condition

Related Studies